Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1763
  • Dowloads 107

Case Reports

Open Access

Glycogen-rich clear cell breast carcinoma in a luminal-Her2 molecular subtype: is it only a pathologic feature or is there a gap in therapy?

  • A. Tampakis1,†,*,
  • E. C. Tampaki2,†
  • P. Korkolopoulou3
  • G. Rigas4
  • K. Kontzoglou2
  • E. Patsouris3
  • G. Kouraklis2

1Department of Surgery, University Hospital of Basel, Basel, Switzerland

22nd Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

31st Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

4General Hospital of Volos, “Achillopouleion”, Volos, Greece

DOI: 10.12892/ejgo4004.2018 Vol.39,Issue 3,June 2018 pp.493-495

Published: 10 June 2018

*Corresponding Author(s): A. Tampakis E-mail: athantamp@hotmail.com

† These authors contributed equally.

PDF (435.45 kB) View Full-text

Abstract

Introduction: Glycogen-rich clear cell carcinoma (GRCC) of the breast is a rare variant of primary breast carcinoma that is characterized by carcinoma cells containing an optically clear cytoplasm and intracytoplasmic glycogen. An ongoing debate exists whether it harbors aggressive clinical features. Case Report: The authors report the case of a 41-year-old Greek female patient, who had noticed a lump in the upper inner quadrant of the left breast. The patient underwent a left radical mastectomy with sentinel lymph node excisional biopsy and the histopathological diagnosis revealed a pT3pN0cM0R0 luminal-HER2 GRCC invasive carcinoma of the breast. Although the patient received aggressive multimodal adjuvant chemoradiation, as well as hormone therapy, she recurred 31 months after the operation with cervical, supraclavicular, and mediastinal lymph node metastasis on the left side. Conclusions: The biological behavior of GRCC is difficult to predict. According to the presented data, a gap in therapy might exist regarding the treatment of GRCC. Larger studies should be performed in order to refute or confirm this hypothesis.

Keywords

Glycogen rich clear cell carcinoma; HER2; GCDFP-15; Ductal breast carcinoma; In situ component.

Cite and Share

A. Tampakis,E. C. Tampaki,P. Korkolopoulou,G. Rigas,K. Kontzoglou,E. Patsouris,G. Kouraklis. Glycogen-rich clear cell breast carcinoma in a luminal-Her2 molecular subtype: is it only a pathologic feature or is there a gap in therapy?. European Journal of Gynaecological Oncology. 2018. 39(3);493-495.

URL:

https://www.ejgo.net/articles/10.12892/ejgo4004.2018

References

[1] Toikkanen S., Joensuu H.: “Glycogen-rich clear-cell carcinoma of the breast: A clinicopathologic and flow cytometric study”. Hum. Pathol., 1991, 22, 81.

[2] Hayes M.M., Seidman J.D., Ashton M.A.: “Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases”. Am. J. Surg. Pathol., 1995, 19, 904.

[3] Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H.: “Breast cancer subtypes and the risk of local and regional relapse”. J. Clin. Oncol., 2010, 28, 1684.

[4] Ma X., Han Y., Fan Y., Cao X., Wang X.: “Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast”. Breast J., 2014, 20, 166.

[5] Dina R., Eusebi V.: “Clear cell tumors of the breast”. Semin. Diagn. Pathol., 1997, 14, 175.

[6] Fisher E.R., Tavares J., Bulatao I. S., Sass R., Fisher B.: “Glycogenrich, clear cell breast cancer: With comments concerning other clear cell variants”. Hum Pathol., 1985, 16, 1085.

[7] Soares J., Tomasic G., Bucciarelli E., Eusebi V.: “Intralobular growth of myoepithelial cell carcinoma of the breast”. Virchows Arch., 1994, 425, 205.

[8] Kuroda H., Sakamoto G., Ohnisi K., Itoyama S.: “Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast”. Breast Cancer, 2005, 12, 189.

[9] Pak I., Kutun S., Celik A., Alyanak A., Ardic F., Cetin A.: “Glycogen- rich “clear cell” carcinoma of the breast”. Breast J., 2005, 11, 288.

[10] Markopoulos C., Mantas D., Philipidis T., Kouskos E., Antonopoulou Z., Hatzinikolaou M., et al.: “Glycogen-rich clear cell carcinoma of the breast”. World J. Surg. Oncol., 2008, 6, 44.

[11] Mizukami Y., Takayama T., Takemura A., Ichikawa K., Onoguchi M., Taniya T.: “Glycogen-rich clear cell carcinoma of the breast: A case report”. J. Med. Ultrason., 2009, 36, 39.

[12] Varga Z., Caduff R.: “Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments”. Breast Cancer Res. Treat., 1999, 57, 215.

[13] Hull M. T., Priest J. B., Broadie T. A., Ransburg R. C., McCarthy L. J.: “Glycogen-rich clear cell carcinoma of the breast: A light and electron microscopic study”. Cancer, 1981, 48, 2003.

[14] Farquhar C., Marjoribanks J., Lethaby A., Azhar M.: “High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer”. Cochrane Database Syst. Rev., 2016, 5, CD003139.

Submission Turnaround Time

Top